Multiple Myeloma Research Foundation (MMRF) – CureCloud Platform

Anne Quinn Young, MPH, Brand President of the MMRF discusses CureCloud, their latest platform designed to provide myeloma patents with their own genomic profile while building a database that combines genomic insights with clinical data to identify trends and support further developments. The CureCloud mission is to find and develop cures for all myeloma patients based on the fact that all patients can contribute to cures and each patient can benefit from the masses.  

Anne Quinn Young, MPH, is the Brand President at the MMRF and is responsible for overseeing the strategy and execution of the organization’s marketing, communications, patient engagement, and fundraising efforts in support of the organization’s mission to accelerate precision medicine and a cure for every patient.  

Anne has been named to the PharmaVoice 100, and represents the MMRF on a number of working groups and committees including the Direct-to-Patient (DTP) solutions team at the Harvard Business School (HBS) Kraft Precision Medicine Accelerator and the Cancer Support Community Frankly Speaking About Cancer: Multiple Myeloma National Advisory Board. She has co-authored a number of peer-reviewed abstracts and publications on the MMRF Precision Medicine Model and identifying knowledge gaps and opportunities to improve patient empowerment and engagement in optimizing their own outcomes.

Prior to joining the MMRF in 2002, she was a consultant in the Healthcare Practice of Datamonitor, a global market research and business intelligence company. She previously worked in healthcare public relations at Burson-Marsteller and the Chandler Chicco Agency, following a postgraduate internship at the Department of Justice, Antitrust Division. Anne has a Masters of Public Health from the Mailman School of Public Health of Columbia University and graduated cum laude from Dartmouth College with a Bachelor of Arts in Government.

Listen on  Soundcloud.